24 February 2018 - Price would be lower than more potent, injected inhibitors.

Esperion Therapeutics racing to bring its first product to pharmacy shelves, may have found a way to jolt the stagnant market for heart-disease drugs: by undercutting the price of its more powerful rivals.

Even before Esperion knows whether bempedoic acid is effective, the company has formulated a strong position on the drug’s potential price and discussed it with insurers, Chief Executive Officer Tim Mayleben said in an interview Friday. The upshot: It will cost $9 to $10 a day, or less than $4,000 a year.

Read Bloomberg article